In Vitro Colorectal Cancer Screening Tests Market Share 2030
In Vitro Colorectal Cancer Screening Tests Market Share 2030
Segments - In-Vitro Colorectal Cancer Screening Tests Market by Products (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Tumor M2-PK Stool Test, Transferrin Assays, Methylated Gene Testing, and Panel DNA Tests) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
Upcoming
| Report ID :HC-1007
| 4.8 Rating
| 68 Reviews
| 152 Pages
| Format :
Report Description
The global in-vitro colorectal cancer screening tests market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising cases of rectal and colon cancer along with the wide use of novel screening tests with genetic testing.
Colorectal cancer, also called bowel cancer and colon cancer, is a type of cancer that affects the colon and the rectum by uncontrolled and abnormal division of cells leading to the formation of a malignant tumor. In-vitro colorectal cancer, screening tests are done to check symptoms and presence of colorectal cancer. In this test, the detection of colorectal cancer in patients is confirmed by understanding the progression and nature of this cancer. Increasing adoption of unhealthy food habits such as rising consumption of alcohol and tobacco smoking are responsible for inflammatory intestinal conditions, which lead to rising cases of colorectal cancer.
As per a global health report, colorectal cancer is one of the most common forms of cancer that accounts for nearly 10% of all global cancer incidences. These incidences are rising over the last few years. One of the key aspects of the market growth can be attributed to gradually introduction of the novel colorectal tests. These tests either use biomarkers such as tumor M2-PK marker or methylated genes for screening colorectal cancer. A major factor responsible for the market expansion is due to high accuracy of screening and diagnostic procedures, which are offered by these new genetic tests.
Market Trends, Drivers, Restraints, and Opportunities
- Growing prevalence of colorectal cancer due to inactive lifestyle and rising number of the aging population globally are key factors driving the market growth.
- Favorable government regulations regarding the application of cancer screening tests and increasing demand of novel invasive tests are projected to boost the market growth during the forecast period.
- Initiatives taken by private and public players for creating awareness about treatment and pre-diagnosis of colorectal cancer are expected to boost the market growth.
- Improvements in screening technology by using non-invasive methods and introduction of high-speed DNA sequencing using genetic biomarkers are expected to fuel the market growth.
- Lack of reimbursement coverage and number of trained staff handling the screening tests in developing regions are major factors likely to hinder the market expansion.
Scope of the Report
The report on the global in-vitro colorectal cancer screening tests market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
In-Vitro Colorectal Cancer Screening Tests Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Products (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests, Guaiac FOB Stool Test, Immuno-FOB Agglutination Test, Lateral Flow Immuno-FOB Test, Immuno-FOB ELISA Test, Tumor M2-PK Stool Test, Transferrin Assays, Methylated Gene Testing, and Panel DNA Tests) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Abbott Molecular, Beckman Coulter, Alere, Epigenomics, Eiken Chemical, Sysmex, Siemens Healthcare, Quest Diagnostics, Companion Dx, Oncocyte, Merck Millipore, Immunostics, ExiQon, Kyowa Medex, Mode Diagnostics, Randox Laboratories, and R-Biopharm |
Market Segment Insights
Fecal occult blood tests segment is projected to hold a major market share
On the basis of products, the in-vitro colorectal cancer screening tests market is divided into fecal occult blood tests, biomarker tests, CRC DNA screening tests, guaiac FOB stool test, immuno-FOB agglutination test, lateral flow immuno-FOB test, immuno-FOB ELISA test, tumor M2-PK stool test, transferrin assays, methylated gene testing, and panel DNA tests.
The fecal occult blood tests segment is expected to dominate the market during the forecast period due to their increasing use and easy applicability to large number of populations at once. Meanwhile, the immuno-FOB ELISA and immuno-FOB agglutination test segment in combined accounted for a major share of the in-vitro colorectal screening tests market. However, the DNA and biomarker screening tests are the new tests with more accuracy for in-vitro colorectal cancer screening tests. Due to which, the segments are likely to register a high CAGR during the forecast period.
The transferrin assays and methylated gene testing segments are latest developments in the screening tests. In early stages of cancer and before the tumors spread inside human body, using transferrin assays gives valuable information in the screening of precancerous wound. Moreover, the transferrin dipstick test shows accuracy consistent with immuno-FOB stool tests. This is projected to boost the segment growth during the forecast period. Furthermore, the methylated gene testing is also widely adopted due to the prevalence of excessive risk of presence of colorectal cancer.
Asia Pacific is expected to dominate the market
On the basis of regions, the in-vitro colorectal cancer screening tests market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to increasing number of colorectal cancer cases and larger geriatric population base in the region.
On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to rising occurrence of cancer in this region. Over the past decades, the death rate of colorectal cancer has been increasing in this region. National guidelines on colorectal cancer screening are formally adopted in countries such as South Korea, Taiwan, Japan, and Singapore. This leads to the rapid expansion of the market in the region.
Segments
Segments Covered in the ReportThe global in-vitro colorectal cancer screening tests market has been segmented on the basis of
Products
- Fecal Occult Blood Tests
- Biomarker Tests
- CRC DNA Screening Tests
- Guaiac FOB Stool Test
- Immuno-FOB Agglutination Test
- Lateral Flow Immuno-FOB Test
- Immuno-FOB ELISA Test
- Tumor M2-PK Stool Test
- Transferrin Assays
- Methylated Gene Testing
- Panel DNA Tests
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Abbott Molecular
- Beckman Coulter
- Alere
- Epigenomics
- Eiken Chemical
- Sysmex
- Siemens Healthcare
- Quest Diagnostics
- Companion Dx
- Oncocyte
- Merck Millipore
- Immunostics
- ExiQon
- Kyowa Medex
- Mode Diagnostics
- Randox Laboratories
- R-Biopharm
Competitive Landscape
Key players competing in the in-vitro colorectal cancer screening tests market include Abbott Molecular, Beckman Coulter, Alere, Epigenomics, Eiken Chemical, Sysmex, Siemens Healthcare, Quest Diagnostics, Companion Dx, Oncocyte, Merck Millipore, Immunostics, ExiQon, Kyowa Medex, Mode Diagnostics, Randox Laboratories, and R-Biopharm.
Some of these key players are majorly focusing on collaboration strategy to increase product portfolio. Moreover, they are actively investing on R&D for the development of CRC DNA and biomarker screening tests along with other business strategies such as mergers, acquisitions, partnerships, and capacity expansion to increase their market shares.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. In-Vitro Colorectal Cancer Screening Tests Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. In-Vitro Colorectal Cancer Screening Tests Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. In-Vitro Colorectal Cancer Screening Tests Market - Supply Chain
4.5. Global In-Vitro Colorectal Cancer Screening Tests Market Forecast
4.5.1. In-Vitro Colorectal Cancer Screening Tests Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. In-Vitro Colorectal Cancer Screening Tests Market Size (000’ Units) and Y-o-Y Growth
4.5.3. In-Vitro Colorectal Cancer Screening Tests Market Absolute $ Opportunity
5. Global In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Types
5.3.1. Fecal Occult Blood Tests
5.3.2. Biomarker Tests
5.3.3. CRC DNA Screening Tests
5.3.4. Guaiac FOB Stool Test
5.3.5. Immuno-FOB Agglutination Test
5.3.6. Lateral Flow Immuno-FOB Test
5.3.7. Immuno-FOB ELISA Test
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global In-Vitro Colorectal Cancer Screening Tests Demand Share Forecast, 2019-2026
7. North America In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Types
7.4.1. Fecal Occult Blood Tests
7.4.2. Biomarker Tests
7.4.3. CRC DNA Screening Tests
7.4.4. Guaiac FOB Stool Test
7.4.5. Immuno-FOB Agglutination Test
7.4.6. Lateral Flow Immuno-FOB Test
7.4.7. Immuno-FOB ELISA Test
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America In-Vitro Colorectal Cancer Screening Tests Demand Share Forecast, 2019-2026
8. Latin America In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Types
8.4.1. Fecal Occult Blood Tests
8.4.2. Biomarker Tests
8.4.3. CRC DNA Screening Tests
8.4.4. Guaiac FOB Stool Test
8.4.5. Immuno-FOB Agglutination Test
8.4.6. Lateral Flow Immuno-FOB Test
8.4.7. Immuno-FOB ELISA Test
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America In-Vitro Colorectal Cancer Screening Tests Demand Share Forecast, 2019-2026
9. Europe In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Types
9.4.1. Fecal Occult Blood Tests
9.4.2. Biomarker Tests
9.4.3. CRC DNA Screening Tests
9.4.4. Guaiac FOB Stool Test
9.4.5. Immuno-FOB Agglutination Test
9.4.6. Lateral Flow Immuno-FOB Test
9.4.7. Immuno-FOB ELISA Test
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe In-Vitro Colorectal Cancer Screening Tests Demand Share Forecast, 2019-2026
10. Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Types
10.4.1. Fecal Occult Blood Tests
10.4.2. Biomarker Tests
10.4.3. CRC DNA Screening Tests
10.4.4. Guaiac FOB Stool Test
10.4.5. Immuno-FOB Agglutination Test
10.4.6. Lateral Flow Immuno-FOB Test
10.4.7. Immuno-FOB ELISA Test
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific In-Vitro Colorectal Cancer Screening Tests Demand Share Forecast, 2019-2026
11. Middle East & Africa In-Vitro Colorectal Cancer Screening Tests Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa In-Vitro Colorectal Cancer Screening Tests Market Size and Volume Forecast by Types
11.4.1. Fecal Occult Blood Tests
11.4.2. Biomarker Tests
11.4.3. CRC DNA Screening Tests
11.4.4. Guaiac FOB Stool Test
11.4.5. Immuno-FOB Agglutination Test
11.4.6. Lateral Flow Immuno-FOB Test
11.4.7. Immuno-FOB ELISA Test
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa In-Vitro Colorectal Cancer Screening Tests Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global In-Vitro Colorectal Cancer Screening Tests Market: Market Share Analysis
12.2. In-Vitro Colorectal Cancer Screening Tests Distributors and Customers
12.3. In-Vitro Colorectal Cancer Screening Tests Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Abbott Molecular
12.4.2. Beckman Coulter
12.4.3. Alere
12.4.4. Epigenomics
12.4.5. Eiken Chemical
12.4.6. Sysmex
12.4.7. Siemens Healthcare
12.4.8. Quest Diagnostics
Methodology
Related Reports
Some other reports from this category!
Our Clients
